moxifloxacin has been researched along with Conjunctivitis, Bacterial in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Kozlova, A; Michael, A; Palazzolo, L | 1 |
| Borgman, CJ | 1 |
| Baiza-Durán, L; Casillas-Magallanes, M; Gómez-Bastar, PA; González-Lomelí, M; Lizárraga-Corona, A; Mercado-Sesma, AR; Montoya-Sánchez, IM; Mora-González, A; Ochoa-Tabares, JC; Olvera-Montaño, O; Oregon-Miranda, AA; Orozco-Carroll, M; Páez-Garza, JH; Pérez-Balbuena, AL; Sandoval-Delgadillo, LI; Saucedo-Rodríguez, LR; Villanueva-Najera, MA | 1 |
| Desai, AR; Maulvi, FA; Ranch, KM; Shah, DO; Shukla, MR; Singhania, SS; Tannk, AS; Vyas, BA | 1 |
| Blanco, C; Núñez, MX | 1 |
| Chan, I; Cockerham, G; Dhatt, HS; Egbert, PR; Fisher, E; Kaspar, HM; Montague, A; Paterno, J; Singh, K; Ta, CN | 1 |
| Brunner, LS; Comstock, TL; Haas, W; McDonald, MB; Morris, TW; Paterno, MR; Protzko, EE; Usner, DW | 1 |
| Bertino, JS; Zhang, JZ | 1 |
| Carter, NJ; Scott, LJ | 1 |
| Bell, B; D'Arienzo, PA; Dajcs, JJ; Jamison, T; Stroman, DW; Wagner, RS | 1 |
| Comstock, TL; Paterno, MR; Pichichero, ME; Usner, DW | 1 |
| Berdeaux, G; Khoshnood, B; Kodjikian, L; Lafuma, A; Laurendeau, C | 1 |
| Alfonso, EC; Almeida, DR; Miller, D | 1 |
| Proksch, JW; Ward, KW | 1 |
| Keating, GM | 1 |
| Benitez-Del-Castillo, J; Kodjikian, L; Stroman, D; Verboven, Y | 1 |
| Bartell, J; Cupp, G; Garber, R; Stroman, D; Tauber, S; Vohra, F | 1 |
| Chee, SP | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Cook, S; Gigliotti, F; Hardy, D; Laverty, S; Malhotra, Y; Murante, B; Topa, D; Wang, H; Williams, L | 1 |
| Montgomery, DB; Silver, LH; Woodside, AM | 1 |
| Maguen, E; Morgan, MA | 1 |
| Girgis, D; Kabat, A; O'Brien, T; Ohnsman, C; Ritterband, D | 1 |
4 review(s) available for moxifloxacin and Conjunctivitis, Bacterial
| Article | Year |
|---|---|
Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Clinical Trials as Topic; Conjunctivitis, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2009 |
[Efficacy of moxifloxacin in treating bacterial conjunctivitis: a meta-analysis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Odds Ratio; Ofloxacin; Ophthalmic Solutions; Patient Dropouts; Placebos; Quinolines; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome | 2010 |
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.
Topics: Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Conjunctivitis, Bacterial; Eye; Fluoroquinolones; Humans; Moxifloxacin; Multicenter Studies as Topic; Ophthalmic Solutions; Quinolines; Randomized Controlled Trials as Topic | 2011 |
Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Topics: Adult; Aza Compounds; Child; Child, Preschool; Clinical Trials as Topic; Conjunctivitis, Bacterial; Fluoroquinolones; Humans; Infant; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2005 |
6 trial(s) available for moxifloxacin and Conjunctivitis, Bacterial
| Article | Year |
|---|---|
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Conjunctivitis, Bacterial; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Oxazines; Staphylococcus; Young Adult | 2018 |
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azepines; Child; Child, Preschool; Conjunctiva; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Infant; Male; Microscopy, Acoustic; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Quinolines; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Treatment Outcome; Visual Acuity | 2009 |
Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Child, Preschool; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Young Adult | 2011 |
Moxifloxacin punctum plug for sustained drug delivery.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Cataract; Cataract Extraction; Conjunctivitis, Bacterial; Delayed-Action Preparations; Double-Blind Method; Drug Delivery Systems; Endpoint Determination; Feasibility Studies; Female; Fluoroquinolones; Humans; Intraocular Pressure; Male; Middle Aged; Moxifloxacin; Postoperative Complications; Prospective Studies; Quinolines; Tears; Time Factors | 2012 |
A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children.
Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Child, Preschool; Conjunctiva; Conjunctivitis, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Infant; Male; Moraxella catarrhalis; Moxifloxacin; Ophthalmic Solutions; Polymyxin B; Quinolines; Single-Blind Method; Streptococcus pneumoniae; Trimethoprim | 2013 |
Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Conjunctivitis, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2007 |
14 other study(ies) available for moxifloxacin and Conjunctivitis, Bacterial
| Article | Year |
|---|---|
Neisseria sicca: A Rare Cause of Bacterial Conjunctivitis.
Topics: Anti-Bacterial Agents; Ceftriaxone; Conjunctivitis, Bacterial; Humans; Male; Moxifloxacin; Neisseria sicca; Neisseriaceae Infections | 2020 |
Recurrent conjunctivitis secondary to Gram-positive bacillus, Bacillus thuringiensis.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Bacillus thuringiensis; Conjunctivitis, Bacterial; Dexamethasone; Drug Therapy, Combination; Eye Infections, Bacterial; Glucocorticoids; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Recurrence; Tobramycin | 2018 |
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis.
Topics: Animals; Anti-Bacterial Agents; Conjunctivitis, Bacterial; Contact Lenses; Drug Delivery Systems; Drug Liberation; Female; Fluoroquinolones; Hyaluronic Acid; Male; Moxifloxacin; Rabbits; Staphylococcus aureus | 2018 |
Antibiotic susceptibility of staphylococci isolates from patients with chronic conjunctivitis: including associated factors and clinical evaluation.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Chronic Disease; Conjunctivitis, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Treatment Outcome; Vancomycin | 2013 |
Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application.
Topics: Administration, Topical; Aged; Aza Compounds; Conjunctivitis, Bacterial; Drug Administration Schedule; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Prospective Studies; Quinolines; Time Factors | 2008 |
Besifloxacin ophthalmic suspension 0.6%.
Topics: Administration, Topical; Anti-Bacterial Agents; Antifungal Agents; Aza Compounds; Azepines; Colony Count, Microbial; Conjunctivitis, Bacterial; DNA Gyrase; DNA Topoisomerase IV; Double-Blind Method; Drug Administration Schedule; Eye; Fluoroquinolones; Humans; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suspensions | 2010 |
Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Ciprofloxacin; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors | 2010 |
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Aza Compounds; Azepines; Child; Child, Preschool; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Humans; Infant; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Tsukamurella: an emerging opportunistic ocular pathogen.
Topics: Actinomycetales; Actinomycetales Infections; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Conjunctivitis, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Gentamicins; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Opportunistic Infections; Quinolines; Tobramycin | 2010 |
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Conjunctivitis, Bacterial; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus Infections; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Streptococcal Infections | 2010 |
The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Conjunctivitis, Bacterial; Cost-Benefit Analysis; Europe; Fluoroquinolones; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
Topics: Adult; Aza Compounds; Child; Conjunctivitis, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Pregnancy; Quinolines | 2004 |
A case of vancomycin-resistant enterococcus conjunctivitis and its clinically successful topical treatment.
Topics: Aged; Antitubercular Agents; Aza Compounds; Conjunctivitis, Bacterial; Enterococcus faecalis; Fluoroquinolones; Follow-Up Studies; Gram-Positive Bacterial Infections; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines; Vancomycin Resistance | 2007 |